Direct-to-Consumer GLP-1 Subscription Services Face Growing Scrutiny
Subscription-style telehealth weight-loss services have drawn attention from regulators and consumer advocates over marketing claims and clinical oversight.
By the GLP Semaglutide editorial team · Last updated March 1, 2026
Subscription-based telehealth platforms offering GLP-1 prescriptions have grown quickly, and that growth has drawn scrutiny from regulators over how clinical evaluations are conducted, how compounded products are marketed, and whether advertising claims are adequately substantiated.
What regulators have focused on
The FTC has authority over deceptive advertising claims, while state medical boards oversee whether the clinical evaluation model used by a given platform meets telemedicine practice standards — these are separate regulatory lanes that can both apply to the same company.
What to look for as a consumer
Clear disclosure of whether a prescription is for an FDA-approved product or a compounded alternative, a genuine clinical evaluation rather than a rubber-stamp questionnaire, and transparent pricing are reasonable baseline expectations.
Primary sources